Changes to the Complera (Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate) Labeling

"On June 5, 2014, FDA approved changes to the Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) fixed-dose combination tablet labeling to include rilpivirine dose adjustment information when Complera is coadministered with rifabutin."

The updated labeling for Complera is available at the FDA website.

More information is available:

FDA: Press release
AIDSinfo: Patient fact sheet on Complera

Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - June 20, 2014 Category: Infectious Diseases Source Type: news